CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 163 enrolled
Drug / intervention
AGN-199201 ophthalmic solution +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02595528
NCT02595528Phase 2Completed
CompareCT.gov

A Phase 2, Multicenter, Double-masked, Randomized, Vehicle-Controlled, Study of the Concurrent Use of AGN-190584 and AGN-199201 in Patients With Presbyopia

Allergan·interventional·Posted Nov 3, 2015·Updated Dec 22, 2020

In Brief

A Phase 2 clinical trial evaluating AGN-199201 ophthalmic solution, AGN-190584 ophthalmic solution, and 3 other interventions for Presbyopia. Completed, enrolled 163 participants across 20 sites.

Detailed Summary

This study will identify the optimum concentrations of AGN-199201 and AGN-190584 when dosed in combination once a day for the improvement of uncorrected near visual acuity in participants with presbyopia (inability to focus on items close-up).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPresbyopia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 3, 2015
Enrollment StartApr 29, 2016
Primary CompletionOct 18, 2017
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 10.7 years ago

Interventions

AGN-199201 ophthalmic solutiondrug

1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.

AGN-190584 ophthalmic solutiondrug

1 drop AGN-190584 ophthalmic solution doses A, B and C in the eye.

AGN-190584 vehicledrug

Vehicle to AGN-190584

AGN-199201 + AGN-190584 Combinationdrug

1 drop AGN-199201 and AGN-190584 fixed combination ophthalmic solution in the eye.

AGN-199201 vehicledrug

Vehicle to AGN-199201